BioMarin Pharmaceutical Inc.

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

10 سبتمبر 2019 14:45:06 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

09 سبتمبر 2019 14:50:21 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

15 أغسطس 2019 14:45:01 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

14 أغسطس 2019 14:45:02 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

13 أغسطس 2019 14:45:00 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

12 أغسطس 2019 16:44:24 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

06 أغسطس 2019 15:30:54 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

05 أغسطس 2019 15:11:20 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

02 أغسطس 2019 14:45:02 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

31 يوليو 2019 20:08:40 بحسب NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

30 يوليو 2019 14:47:08 بحسب NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 أكتوبر 2018 15:48:59 بحسب NetDania Notify

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 ديسمبر 2016 13:29:22 بحسب Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 نوفمبر 2016 12:30:46 بحسب Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 أكتوبر 2016 21:03:46 بحسب Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 أكتوبر 2016 22:01:21 بحسب Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 أكتوبر 2016 21:01:29 بحسب Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 أكتوبر 2016 13:31:09 بحسب Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 سبتمبر 2016 13:54:15 بحسب Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 سبتمبر 2016 13:38:09 بحسب Nasdaq GlobeNewswire